EGFR and non-small cell lung carcinoma: Aumolertinib, as a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor (<i>EGFR</i>-TKI), has been widely employed as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with <i>EGFR</i> mutation.